Heart Protection Medicine Before and After Heart Surgery
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether a medication called vericiguat, given around the time of heart surgery, can help protect your heart and prevent heart failure complications. You'll receive the study drug or a placebo before and after surgery and be monitored for 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–80 years old and scheduled for heart surgery (bypass, valve repair/replacement, or major vessel surgery)
- Your doctor has identified you as high-risk for heart failure or you have known heart function problems
- Your resting blood pressure is at least 100 mmHg (not too low)
- You can commit to 6 months of follow-up visits after surgery
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
- You don't have severe liver, kidney, or blood disorders, active infections, or severe malnutrition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 trial studies vericiguat-like stimulation (a type of medicine that affects blood-vessel signaling) around the time of planned open-heart surgery. It aims to see whether this can change blood-vessel “reactivity” and reduce injury to organs during and after surgery.
This trial tests whether vericiguat can improve heart function in people with stable heart failure and a reduced pumping ability. It may help if you have not needed hospital or IV treatments for worsening heart failure in the last 6 months.
This trial tests if starting vericiguat early after a heart attack helps patients with heart failure. It's for people who had a procedure to open a blocked artery and then developed heart failure within two weeks.
This trial tests a medication called Vericiguat for people with heart failure and a weak heart pump after a past heart attack. It aims to see if the drug can help improve your condition.
This trial tests if adding the drug vericiguat to standard care can help people with heart failure and a reduced pumping ability who have a CardioMEMS monitor. It looks for improved pressure readings in your lung artery to guide treatment.
This study tests whether a medication called vericiguat can improve chest pain caused by problems in the tiny blood vessels of the heart (not by large blockages). You may be a candidate if you have stable chest pain, are 40–75, and have had tests showing your heart's small vessels aren't working well.
Hear when a new Cardio Vascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.